Zevin Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.8M Sell
12,300
-1,437
-10% -$1.47M 2.07% 19
2026
Q1
$12.6M Buy
13,737
+644
+5% +$653K 1.75% 25
2025
Q4
$14.1M Buy
13,093
+3,918
+43% +$3.75M 1.89% 23
2025
Q3
$7M Sell
9,175
-2,956
-24% -$2.2M 1.02% 42
2025
Q2
$9.46M Sell
12,131
-404
-3% -$314K 1.36% 35
2025
Q1
$10.4M Buy
+12,535
New +$10.4M 1.64% 30

Other funds holding LLY

Zevin Asset Management's LLY Position: Q2 2026 in Review

Zevin Asset Management reduced its Eli Lilly (LLY) stake by 10% in Q2 2026, selling an estimated $1.47M and leaving 12,300 shares worth $14.8M. The position accounts for 2.07% of the portfolio, ranked #19.

Zevin Asset Management first reported a position in LLY in Q1 2025 and has held it in 6 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Zevin Asset Management held 12,300 shares of Eli Lilly worth $14.8M as of Q2 2026.
  • Zevin Asset Management sold 1,437 Eli Lilly shares in Q2 2026, an estimated $1.47M.
  • Eli Lilly made up 2.07% of Zevin Asset Management's portfolio in Q2 2026, its #19 holding.
  • Zevin Asset Management first reported a position in Eli Lilly in Q1 2025 and has held it in 6 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Zevin Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.